FHIR IG analytics| Package | hl7.fhir.uv.ebm |
| Resource Type | Composition |
| Id | Composition-370504.json |
| FHIR Version | R6 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: Composition 370504
version: 24; Last updated: 2025-08-18 13:22:42+0000; Language: en
Profile: OutcomeMeasureReport
ArtifactPublicationStatus: Active
url: https://fevir.net/resources/Composition/370504
identifier: FEvIR Object Identifier/370504, FEvIR Linking Identifier/NCT03640312-outcome-measure-report
status: Final
type: Outcome Measure Report
date: 2025-08-18 13:22:42+0000
author: [No author listed.]
title: Outcome Measures Report for NCT03640312
custodian: Computable Publishing LLC
| Type | Target[x] |
| Cite As | Outcome Measures Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370504. Revised 2025-08-18. Available at: https://fevir.net/resources/Composition/370504. Computable resource at: https://fevir.net/resources/Composition/370504. |
FHIR
FHIRsmith{
"resourceType": "Composition",
"id": "370504",
"meta": {
"versionId": "24",
"lastUpdated": "2025-08-18T13:22:42.074Z",
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"
]
},
"language": "en",
"text": {
"status": "extensions",
"div": "<!-- snip (see above) -->"
},
"extension": [
{
"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code": "active",
"display": "Active"
}
]
}
}
],
"url": "https://fevir.net/resources/Composition/370504",
"identifier": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "FEvIR Object Identifier"
},
"system": "https://fevir.net/FOI",
"value": "370504",
"assigner": {
"display": "Computable Publishing LLC"
}
},
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-outcome-measure-report",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"status": "final",
"type": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "OutcomeMeasureReport",
"display": "OutcomeMeasureReport"
}
],
"text": "Outcome Measure Report"
},
"date": "2025-08-18T13:22:42.074Z",
"author": [
{
"display": "[No author listed.]"
}
],
"title": "Outcome Measures Report for NCT03640312",
"custodian": {
"reference": "Organization/118079",
"type": "Organization",
"display": "Computable Publishing LLC"
},
"relatesTo": [
{
"type": "cite-as",
"targetMarkdown": "Outcome Measures Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370504. Revised 2025-08-18. Available at: https://fevir.net/resources/Composition/370504. Computable resource at: https://fevir.net/resources/Composition/370504."
}
],
"section": [
{
"title": "Change in Mean Systolic Blood Pressure at 12 weeks",
"focus": {
"reference": "EvidenceVariable/367882",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-primaryOutcome-0",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367882",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-primaryOutcome-0",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367903",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-primaryOutcomeMeasure-0--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367904",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-primaryOutcomeMeasure-0--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367941",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-primaryOutcomeMeasure-0-OutcomeAnalysis-0-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Mean Systolic Blood Pressure at 6 weeks",
"focus": {
"reference": "EvidenceVariable/367883",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-0",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Systolic Blood Pressure at 6 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Mean Systolic Blood Pressure at 6 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367883",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-0",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Systolic Blood Pressure at 6 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367905",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-0--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367906",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-0--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367942",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-0-OutcomeAnalysis-1-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Change in Mean Diastolic Blood Pressure at 6 weeks",
"focus": {
"reference": "EvidenceVariable/367884",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-1",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Change in Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367884",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-1",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367907",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-1--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367908",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-1--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367943",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-1-OutcomeAnalysis-2-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Mean Diastolic Blood Pressure at 6 weeks",
"focus": {
"reference": "EvidenceVariable/367885",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-2",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367885",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-2",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367909",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-2--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367910",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-2--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367944",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-2-OutcomeAnalysis-3-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Proportion of Patients With Hypertension Control at 6 and 12 weeks",
"focus": {
"reference": "EvidenceVariable/367886",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-3",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 and 12 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/370506",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-3-6-weeks-",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367911",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-3-6-weeks-OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367912",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-3-6-weeks-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312"
}
]
},
{
"title": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/370507",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-3-12-weeks-",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367913",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-3-12-weeks-OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367914",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-3-12-weeks-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312"
}
]
}
]
},
{
"title": "Outcome Analysis List for Proportion of Patients With Hypertension Control at 6 and 12 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
],
"text": "OutcomeAnalysisList"
},
"focus": {
"reference": "EvidenceVariable/367886",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-3",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367945",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-3-OutcomeAnalysis-4-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
},
{
"title": "Number of Patients Requiring Step up Treatment at 6 weeks",
"focus": {
"reference": "EvidenceVariable/367887",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-4",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Number of Patients Requiring Step up Treatment at 6 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Number of Patients Requiring Step up Treatment at 6 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367887",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-4",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Number of Patients Requiring Step up Treatment at 6 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367915",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-4--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367916",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-4--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367946",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-4-OutcomeAnalysis-5-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks",
"focus": {
"reference": "EvidenceVariable/367888",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-5",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367888",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-5",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367917",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-5--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367918",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-5--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367947",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-5-OutcomeAnalysis-6-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Medication Adherence at 12 weeks",
"focus": {
"reference": "EvidenceVariable/367889",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-6",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Medication Adherence at 12 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Medication Adherence at 12 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367889",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-6",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Medication Adherence at 12 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367919",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-6--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367920",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-6--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Medication Adherence at 12 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367948",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-6-OutcomeAnalysis-7-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Health-related Quality of Life at 12 weeks",
"focus": {
"reference": "EvidenceVariable/367890",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-7",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Health-related Quality of Life at 12 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Data are available on only 28 participants in the intervention group for the mental health T score.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/370508",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367921",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367922",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312"
}
]
},
{
"title": "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/370509",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-7-Change-in-Mental-Health-T-score--OPEN---PROMIS---CLOSE--",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367923",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Mental-Health-T-score--OPEN---PROMIS---CLOSE--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367924",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Mental-Health-T-score--OPEN---PROMIS---CLOSE--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312"
}
]
}
]
},
{
"title": "Outcome Analysis List for Health-related Quality of Life at 12 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
],
"text": "OutcomeAnalysisList"
},
"focus": {
"reference": "EvidenceVariable/367890",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-7",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Health-related Quality of Life at 12 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367949",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-7-OutcomeAnalysis-8-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
},
{
"reference": "Evidence/367950",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-7-OutcomeAnalysis-9-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
},
{
"title": "Change in Mean Systolic Blood Pressure at 6 weeks",
"focus": {
"reference": "EvidenceVariable/367891",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-8",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367891",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcome-8",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367925",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-8--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367926",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-8--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367951",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-secondaryOutcomeMeasure-8-OutcomeAnalysis-10-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks",
"focus": {
"reference": "EvidenceVariable/367896",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-0",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367896",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-0",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367927",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-0--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367928",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-0--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367952",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-0-OutcomeAnalysis-11-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks",
"focus": {
"reference": "EvidenceVariable/367897",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-1",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367897",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-1",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367929",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-1--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367930",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-1--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367953",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-1-OutcomeAnalysis-12-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Rate of Adverse Events of Special Interest at 12 weeks",
"focus": {
"reference": "EvidenceVariable/367898",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-2",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Rate of Adverse Events of Special Interest at 12 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Rate of Adverse Events of Special Interest at 12 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367898",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-2",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Rate of Adverse Events of Special Interest at 12 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367931",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-2--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367932",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-2--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367954",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-2-OutcomeAnalysis-13-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Mean Change in Serum Potassium at 12 weeks",
"focus": {
"reference": "EvidenceVariable/367899",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-3",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Potassium at 12 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Mean Change in Serum Potassium at 12 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367899",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-3",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Potassium at 12 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367933",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-3--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367934",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-3--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367955",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-3-OutcomeAnalysis-14-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Mean Change in Serum Sodium at 12 weeks",
"focus": {
"reference": "EvidenceVariable/367900",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-4",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Sodium at 12 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Mean Change in Serum Sodium at 12 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367900",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-4",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Sodium at 12 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367935",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-4--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367936",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-4--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367956",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-4-OutcomeAnalysis-15-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Mean Change in Blood Urea Nitrogen at 12 weeks",
"focus": {
"reference": "EvidenceVariable/367901",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-5",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Blood Urea Nitrogen at 12 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Mean Change in Blood Urea Nitrogen at 12 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367901",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-5",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Blood Urea Nitrogen at 12 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367937",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-5--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367938",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-5--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367957",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-5-OutcomeAnalysis-16-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
},
{
"title": "Mean Change in Serum Creatinine at 12 weeks",
"focus": {
"reference": "EvidenceVariable/367902",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-6",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Creatinine at 12 weeks (NCT03640312)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "QUARTET LDQT",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."
}
]
},
{
"title": "Candesartan",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>"
},
"entry": [
{
"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Mean Change in Serum Creatinine at 12 weeks (NCT03640312)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/367902",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcome-6",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Creatinine at 12 weeks (NCT03640312)"
},
"entry": [
{
"reference": "Evidence/367939",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-6--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312"
},
{
"reference": "Evidence/367940",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-6--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312"
},
{
"reference": "Evidence/367958",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03640312-otherOutcomeMeasure-6-OutcomeAnalysis-17-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312"
}
]
}
]
}
]
}
]
}